



**California Medication Assisted Treatment Expansion Project:**  
**Allowable Expenditures**  
*Frequently Asked Questions*  
*Updated June 2018*

The following information is intended to provide California Medication Assisted Treatment (MAT) Expansion Project contractors with a general list of allowable activities and expenditures under California’s State Targeted Response to the Opioid Crisis grant. For questions regarding specific allowable and unallowable activities and expenditures, please email us at [DHCSMATExpansion@dhcs.ca.gov](mailto:DHCSMATExpansion@dhcs.ca.gov). We encourage your innovations!

Please note that grant funds should only be used when no other funding source exists. Grant funds for allowable expenditures can only be utilized for: (1) services directly attributable to the MAT Expansion Project; (2) services to individuals who are not covered by public or commercial health insurance plans; (3) services to individuals whose coverage has been formally determined to be unaffordable; or (4) services that are not sufficiently covered by an individual’s health insurance plan. Expenditures for services only partially attributable to the Opioid STR grant must have sufficient rationale identifying cost-sharing allocations.

Allowable Expenditures	Unallowable Expenditures
<p><b><u>Personnel</u></b></p> <ul style="list-style-type: none"> <li>• Project Director, Hub Coordinator, and Hub clinician salaries and fringe benefits</li> <li>• MAT Spoke Team staff salaries and fringe benefits</li> <li>• Part-time accountant (at Hub)</li> <li>• Local Opioid Coalition leader salaries and fringe benefits</li> <li>• Consultant/physician to mentor Spoke prescribers (i.e., in-person brief educational visits), coaching, and mentoring.</li> <li>• MAT Technical Assistance provided by physicians, physician assistants, and/or nurse practitioners</li> <li>• Education of communities, physicians, clinicians, and MAT support teams</li> </ul>	<p><b><u>Personnel</u></b></p> <ul style="list-style-type: none"> <li>• Salaries and fringe benefits to personnel not performing MAT Expansion Project activities</li> <li>• Salaries and fringe benefits for personnel performing both grant activities and non-grant activities without sufficient documentation (i.e. payroll records, paystubs, and job descriptions clearly identifying cost-sharing methodologies)</li> <li>• Housing for MAT employees</li> </ul>

<b>Allowable Expenditures</b>	<b>Unallowable Expenditures</b>
<ul style="list-style-type: none"> <li>Reference manuals and tools used for personnel and community education.</li> </ul>	
<p><b><u>Miscellaneous</u></b></p> <ul style="list-style-type: none"> <li>Office supplies, such as pens, pencils, and other supplies necessary to project operation</li> <li>Furniture necessary to project operation, such as additional desks, office chairs, and other minor equipment.</li> <li>Medical equipment necessary to project operation</li> <li>Medication safes to store buprenorphine, naltrexone, and naloxone.</li> <li>Medication lockboxes for patients</li> <li>Deterra Deactivation System pouches</li> <li>Travel reasonably incurred for the MAT Expansion Project paid at the State rate</li> <li>Patient transportation, such as bus passes, taxis, and ride-sharing services</li> <li>Leasing vehicles to disperse MAT to patients (limited scenarios, please contact DHCS for more information)</li> <li>Exam fees for physician and mid-level providers to become DATA 2000 Waivered</li> <li>Medication Disposal Programs</li> </ul>	<p><b><u>Miscellaneous</u></b></p> <ul style="list-style-type: none"> <li>Syringe Exchange programs are unallowable to fund</li> <li>Travel unrelated to MAT Expansion Project operations</li> <li>Travel costs in excess of the State rate</li> <li>Purchasing vehicles to disperse MAT to patients</li> <li>Supplies, equipment, or furniture for use in non-contract operations of the entity</li> <li>Automated External Defibrillators (AED)</li> <li>Methadone safes</li> <li>Natural remedies (herbs, acupuncture, and other therapies)</li> </ul>
<p><b><u>Infrastructure</u></b></p> <ul style="list-style-type: none"> <li>Minor facility improvements necessary for expansion of OUD prevention, treatment, and recovery services up to 5% of total budget such as <ul style="list-style-type: none"> <li>Dispensing Window addition or improvement</li> <li>Minor internal office infrastructure, such as adding walls or doors to house personnel</li> </ul> </li> <li>Telehealth infrastructure up to 5% to include: <ul style="list-style-type: none"> <li>Hardware such as: desktops, monitors, laptops, tablets, servers, and webcams</li> </ul> </li> </ul>	<p><b><u>Infrastructure</u></b></p> <ul style="list-style-type: none"> <li>Infrastructure costs exceeding 5%</li> <li>Facility improvements unrelated to the expansion of OUD prevention, treatment, and recovery services</li> <li>Facility improvements to building foundation, roofing, heating and air conditioning, or other structural improvements</li> <li>Purchase of building</li> <li>Telehealth infrastructure: <ul style="list-style-type: none"> <li>Structural development to integrate broadband lines</li> <li>Telehealth kiosks</li> </ul> </li> </ul>

<b>Allowable Expenditures</b>	<b>Unallowable Expenditures</b>
<ul style="list-style-type: none"> <li>○ Software and Broadband subscriptions</li> <li>○ Improvements to electronic health records, adding electronic forms, and other data infrastructure</li> </ul>	<ul style="list-style-type: none"> <li>○ Telehealth equipment to treat patients without OUD diagnosis</li> </ul>
<p><b><u>Treatment Services</u></b></p> <ul style="list-style-type: none"> <li>• Medications must be for patients with an OUD diagnosis</li> <li>• Methadone</li> <li>• Buprenorphine <ul style="list-style-type: none"> <li>○ Suboxone</li> <li>○ Subutex</li> <li>○ Sublocade</li> </ul> </li> <li>• Naltrexone</li> <li>• Naloxone <ul style="list-style-type: none"> <li>○ Narcan (at Public Interest Price where no other funding source exists)</li> </ul> </li> <li>• Disulfiram for patients with OUD diagnosis</li> <li>• All other FDA-approved medications for treatment of OUD</li> <li>• NSS-2 Bridge Device</li> <li>• Services for incarcerated patients with OUD</li> <li>• Residential treatment for patients with OUD</li> <li>• Provider reimbursement for time spent treating uninsured and/or underinsured patients</li> <li>• Counseling in Spokes if not paid through another funding source</li> </ul>	<p><b><u>Treatment Services</u></b></p> <ul style="list-style-type: none"> <li>• Non-FDA approved medications</li> <li>• Non-FDA approved devices</li> <li>• Services for patients that are not CA H&amp;SS patients</li> <li>• Direct payments to individuals to encourage attendance and/or attainment of prevention or treatment goals</li> <li>• Medication costs for Medi-Cal beneficiaries</li> <li>• Buprenorphine inductions in Emergency Departments</li> </ul>
<p><b><u>Outreach</u></b></p> <ul style="list-style-type: none"> <li>• Costs of meetings, conventions, convocations, or other events directly related to MAT Expansion Project operations</li> <li>• Cost of materials necessary to promoting MAT Expansion Project activities only</li> </ul>	<p><b><u>Outreach</u></b></p> <ul style="list-style-type: none"> <li>• Costs of meetings, conventions, convocations, or other events related to other activities of the entity</li> <li>• Costs of promotional items and memorabilia, including models, gifts, and souvenirs related to other activities of the entity</li> </ul>

<b>Allowable Expenditures</b>	<b>Unallowable Expenditures</b>
<ul style="list-style-type: none"><li>• Advertising costs directly related to contracted services</li><li>• Outreach to local stakeholders, such as providers, community health clinics, law enforcement, and Local Opioid Coalitions.</li></ul>	<ul style="list-style-type: none"><li>• Meals are generally unallowable unless they are an integral part of a conference grant or specifically stated as an allowable expense</li><li>• Sporting events and entertainment</li><li>• Alcoholic beverages</li></ul>